<DOC>
	<DOC>NCT01270087</DOC>
	<brief_summary>The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.</brief_summary>
	<brief_title>The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis of rheumatoid arthritis Fulfillment of the American College of Rheumatology 1987 criteria for rheumatoid arthritis Active disease despite treatment with at least one disease modifying antirheumatic drug Treatment with adalimumab indicated according to the the patient's rheumatologist At least six swollen joints in 28joint index CRP &gt; 8 mg / L within the last three months Treatment with antiTNF drugs in the last three months Treatment with intravenous corticosteroids within fourteen days Ongoing treatment with oral highdose corticosteroids (equivalent to â‰¥ 20 mg of prednisolon daily) or completed such treatment less than fifteen days before inclusion Severe bleeding disorder Extensive or refractory leg ulcers Severe peripheral vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Rheumatoid arthritis, cardiovascular disease, adalimumab</keyword>
</DOC>